On a Tuesday in February, a Sydney paediatric waiting room is unusually full: children with fevers, parents Googling symptoms, and a GP running through rapid tests faster than the receptionist can stack the swabs. The pattern is being repeated in clinics across the country, and it is the backdrop to a 2026 flu season public health authorities are watching very closely.

What is Subclade K, and why is it spreading so fast?

The strain driving the early 2026 wave is H3N2 Subclade K, nicknamed "Super-K" in Australian coverage. It is not a brand-new kind of flu, but it has accumulated an unusual number of mutations in its Hemagglutinin protein, the part of the virus that latches onto human cells [1]. Dr Daniel Layton, a disease prevention and detection expert at CSIRO's Australian Centre for Disease Preparedness, has described Subclade K as a familiar seasonal strain that has drifted enough to slip past some of the immune defences built up by last year's vaccine [1].

That mismatch matters, but not in the way many people assume. Early data from England suggests the 2025-26 northern hemisphere flu vaccine was 72-75% effective at preventing emergency department visits in adolescents and 29-32% effective in adults, broadly on par with previous seasons even when the circulating strain drifted [1]. A separate Harvard Medical School study published in JAMA and reported by ABC News found the same shots produced a weaker antibody response to Subclade K [2], so the vaccine is still softening the blow but doing less of the early intercept work.

Subclade K was first detected in New York in June 2025, after the composition of the 2025-26 northern hemisphere flu shot had already been finalised, so it caught manufacturers on the hop [3]. GISAID sequencing suggests H3N2 Subclade K is driving an estimated 90% of US flu cases [4], and the US CDC has reported roughly 11 million illnesses, 120,000 hospitalisations and 5,000 deaths in the 2025-26 northern hemisphere season, including nine children [3].

A brutal 2025, and an unusual summer wave

The virus arrived in the closing months of the 2025 winter and then refused to leave, producing a summer wave local epidemiologists are still dissecting. In 2025, 1,701 deaths in Australia involved influenza, the highest tally this century, compared with 1,045 in 2024 and 611 in 2023 [5]. The previous worst year on record was 2017, with 1,656 deaths [6].

Between August 2025 and January 2026, more Australians died from influenza (855) than from COVID-19 (493) [7]. The pattern has since reversed, with COVID-19 deaths in February and March 2026 (81) outpacing flu (41), and the flu curve is climbing again as winter approaches [7].

Dr Catherine Bennett, an epidemiologist at Deakin University, has pointed to the Hemagglutinin mutations as the reason prior immunity was less well targeted [5].

"That meant the vaccine, or prior immunity, wasn't as well targeted to this new virus. That's why we saw more cases in this continuation of our winter outbreak. We saw almost a summer wave of influenza that we don't usually see."

The toll has fallen hardest on older Australians. Most deaths from COVID-19, RSV and influenza in 2025 occurred in the over-70 age group [5], and only about 60% of Australians over 65 were vaccinated against flu last year [5]. Overall coverage sat at roughly one in three, well below the level needed to slow transmission [2].

What's different about the 2026 vaccine

The 2026 Australian flu vaccine has been updated in two important ways. All formulations are now trivalent, protecting against two A strains and one B, after the WHO concluded in 2023 that the B/Yamagata lineage no longer warranted inclusion [8]. The new H3N2 component is an A/Singapore/GP20238/2024-like virus for egg-based vaccines, with a cell-based alternative of A/Sydney/1359/2024 [8].

The country also has access to FluMist, a needle-free nasal spray flu vaccine, for the first time. It is approved for children aged 2 to under 18, with free state programs in NSW (2 to under 5), South Australia (2 to under 5), Queensland (2 to 5) and Western Australia (2 to under 12) [9]. NSW has gone further, expanding free FluMist access to all children aged 2 to 17 from 22 May 2026 [10]. Professor Paul Griffin, Director of Infectious Diseases at Mater Health Services in Brisbane, has emphasised that uptake requires only a single dose, with full protection kicking in about 14 days later [2].

For over-65s, ATAGI recommends Fluad (adjuvanted, NIP-funded) and Fluzone High-Dose (private market), both equally preferable to a standard shot [11]. Cell-based Flucelvax is NIP-funded for people aged 5 to 64 with medical risk conditions [11]. The vaccines began rolling out in April 2026, ahead of the typical June-to-September peak [2][11].

If you had a 2025 shot, an extra booster is not generally recommended, since protection is highest in the first three to four months after vaccination [1]. ATAGI still advises a 2026 dose when it becomes available, even for those vaccinated late in 2025 or early in 2026, because the strain update is meaningful [11].

Antivirals, and who should worry most

At-risk groups for severe flu are well established: adults aged 65 and over, young children (especially under five), pregnant women, Aboriginal and Torres Strait Islander Australians, people with chronic medical conditions, and the immunocompromised [9]. Last summer's hospitalisations hit these groups hardest.

For people who do fall ill, antivirals can shorten the illness and reduce complications if started early. Oseltamivir, sold as Tamiflu, is the most widely used, and Subclade K has not developed resistance to the existing antiviral arsenal [3]. The catch is timing. Tamiflu works best when started within 48 hours of symptom onset, and GPs can prescribe it to eligible patients after a positive test [12]. As the GP Dr Ginny Mansberg told Sunrise, "We can give you the right things that will actually make you feel much better and, more importantly, keep you out of hospital" [12].

Telling Super-K apart from a cold or COVID

Flu typically arrives suddenly, with fever or chills, body aches, headache, extreme tiredness, and a cough or sore throat [1]. A cold usually creeps in over a day or two, with a runny or blocked nose dominating, and rarely produces the kind of prostration flu patients describe. COVID-19 can look almost identical to flu, particularly with the Omicron-derived strains now circulating, although loss of taste or smell, while less common than in 2020, can still be a clue.

An at-home COVID and flu combo test taken in the first few days is the most practical way to sort them out, and CSIRO notes it can guide treatment decisions, even though a negative result does not always rule out flu [1]. Anyone with underlying risk conditions, shortness of breath, chest pain, or confusion should see a GP or attend emergency regardless of test results.

Getting through the season

The message from every Australian authority is the same: vaccination is the single biggest lever, and the 2026 formulation has been deliberately updated to cover Subclade K [2]. Coverage needs to lift well above last year's roughly one-in-three figure, particularly in older adults and young children [2][5][10]. Alongside vaccination, the usual measures still help: stay home when unwell, wash hands, ventilate indoor spaces, and wear a mask in crowded settings if you are vulnerable.

Australia's Chief Medical Officer, Professor Michael Kidd, has written to GPs urging them to recommend vaccination, calling it "one of the most influential drivers of vaccination acceptance" [11]. For parents weighing a needle-free option, or older Australians considering a stronger vaccine, the decision is straightforward. As Professor Griffin has put it, "the main thing that people need to remember is that they just need to get one. It's safe, it's effective, it's available soon" [2].